Business Context and Reporting Period
Zenas BioPharma, Inc. (ZBIO) is a clinical-stage biopharmaceutical company focused on developing immunology and inflammation (I&I) therapies. The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody in Phase 3 trials for IgG4-Related Disease (IgG4-RD) and Phase 2 trials for relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). This Form 10-Q covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $10.0 million | $0 |
| Net Loss | $(52.2) million | $(38.0) million | $(85.8) million | $(65.8) million |
| Net Loss Per Share | $(1.25) | $(24.23) | $(2.05) | $(42.15) |
| Operating Expenses | $55.2 million | $39.7 million | $102.5 million | $67.3 million |
| Cash, Cash Equivalents & Investments | $274.9 million (as of June 30, 2025) | |||
| Accumulated Deficit | $473.2 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue: The company recognized $10.0 million in license and collaboration revenue for the six months ended June 30, 2025, driven by an upfront payment from a new license agreement with Zai Lab (Hong Kong) Limited. No revenue was recognized in the comparable 2024 period.
- Operating Expenses: Total operating expenses increased by $15.5 million in Q2 2025 compared to Q2 2024. Research and Development (R&D) expenses rose $9.2 million, primarily due to increased manufacturing and clinical trial costs for obexelimab. General and Administrative (G&A) expenses increased $6.2 million, driven by higher personnel costs and public company compliance costs.
- Cash Position: Cash, cash equivalents, and investments decreased from $350.8 million at December 31, 2024, to $274.9 million at June 30, 2025. This reduction reflects net cash used in operating activities of $78.8 million and net cash used in investing activities of $198.6 million (primarily purchases of investments) for the six-month period.
Guidance, Outlook, and Risks
- Clinical Milestones: The company expects to report topline results from the Phase 3 INDIGO trial (IgG4-RD) around year-end 2025. Results from the Phase 2 MoonStone trial (RMS) are expected in Q4 2025, and the SunStone trial (SLE) results are expected in mid-2026.
- Liquidity Outlook: Management estimates that existing cash, cash equivalents, and investments of $274.9 million are sufficient to fund operations and capital expenditure requirements into the fourth quarter of 2026.
- Key Risks:
- Capital Requirements: The company anticipates incurring substantial losses for the foreseeable future and will require additional financing to achieve its goals.
- Supply Chain Concentration: Zenas relies on a single third-party manufacturer, WuXi Biologics (located in China), for drug substance and drug product. Risks include geopolitical tensions, potential tariffs, and the proposed BIOSECURE Act which could restrict U.S. federal contracts with certain Chinese biotechnology companies.
- Regulatory Uncertainty: Clinical development is lengthy and expensive with uncertain outcomes. The company faces risks related to patient enrollment, trial results, and regulatory approval.
- Legal Proceedings: A putative securities class action lawsuit was filed in April 2025 regarding the company's IPO.
Investor Verification Checklist
- Verify the sufficiency of the $274.9 million cash runway against the projected burn rate and potential delays in clinical trials.
- Monitor the status of the Phase 3 INDIGO trial for obexelimab in IgG4-RD, with topline results expected late 2025.
- Assess the impact of the proposed BIOSECURE Act and U.S.-China trade relations on the company's sole manufacturing partner, WuXi Biologics.
- Review the progress of the putative securities class action litigation filed in April 2025.
- Track the execution of the new Zai Lab license agreement and the potential for future milestone payments.